Skip to content

MOSAIC IMMUNOENGINEERING, INC.: 10-K filed 2022-01-26

What MOSAIC IMMUNOENGINEERING, INC. reported in its annual report filed 2022-01-26 (fiscal FY 2021): 30 published measures, 79 facts as tagged in accession 0001683168-22-000466.

This filing

Form
10-K (annual report)
Filed
2022-01-26
Fiscal period
fiscal FY 2021
Accession
0001683168-22-000466 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All MOSAIC IMMUNOENGINEERING, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2021-12-31269,494USD
At 2020-12-31457,802USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2021-12-313,068,505USD
At 2020-12-31880,343USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2021-12-31-2,799,011USD
At 2020-12-31-422,541USD
At 2020-05-31-448USD
At 2020-03-310USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2021-12-31226,142USD
At 2020-12-31352,738USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2021-01-01 to 2021-12-31-3,684,478USD365
2020-06-01 to 2020-12-31-842,243USD214
2020-04-01 to 2020-05-31-511USD61
2020-03-30 to 2020-05-31-511USD63

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2021-01-01 to 2021-12-31-679,236USD365
2020-06-01 to 2020-12-31-253,040USD214
2020-03-30 to 2020-05-31500USD63

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2021-01-01 to 2021-12-31525,003USD365
2020-06-01 to 2020-12-3163USD214
2020-03-30 to 2020-05-310USD63

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2021-01-01 to 2021-12-3127,637USD365
2020-06-01 to 2020-12-31605,215USD214
2020-03-30 to 2020-05-310USD63

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2021-12-31-4,527,232USD
At 2020-12-31-842,754USD

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2021-01-01 to 2021-12-31-0.55USD/shares365
2020-06-01 to 2020-12-31-1.12USD/shares214
2020-03-30 to 2020-05-310USD/shares63

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2021-01-01 to 2021-12-31-0.55USD/shares365
2020-06-01 to 2020-12-31-1.12USD/shares214
2020-03-30 to 2020-05-310USD/shares63

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2021-01-01 to 2021-12-312,400USD365
2020-06-01 to 2020-12-311,600USD214
2020-03-30 to 2020-05-310USD63

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2021-01-01 to 2021-12-311,308,008USD365
2020-06-01 to 2020-12-3145,708USD214

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2021-12-31269,494USD
At 2020-12-31457,802USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2021-12-312,333,357USD
At 2020-12-31880,343USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2021-12-31113,513USD
At 2020-12-3186,014USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2021-01-01 to 2021-12-313,501,166USD365
2020-06-01 to 2020-12-31835,632USD214
2020-03-30 to 2020-05-31511USD63

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2021-01-01 to 2021-12-311,456,119USD365
2020-06-01 to 2020-12-31342,727USD214
2020-03-30 to 2020-05-310USD63

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2021-12-317,241,137shares
At 2020-12-31805,803shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2021-12-31226,142USD
At 2020-12-31352,738USD
At 2020-05-31500USD
At 2020-03-290USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2021-12-311,728,148USD
At 2020-12-31420,198USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2021-12-31724,247USD
At 2020-12-31267,401USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2021-12-310USD
At 2020-12-310USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2021-01-01 to 2021-12-310USD365
2020-06-01 to 2020-12-31-5,102USD214
2020-03-30 to 2020-05-310USD63

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2021-01-01 to 2021-12-312,045,047USD365
2020-06-01 to 2020-12-31492,905USD214
2020-03-30 to 2020-05-31511USD63

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2021-01-01 to 2021-12-31-180,912USD365
2020-06-01 to 2020-12-31-5,011USD214
2020-03-30 to 2020-05-310USD63

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

PeriodValueUnitDays
2021-01-01 to 2021-12-312,400USD365
2020-06-01 to 2020-12-311,600USD214

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2021-01-01 to 2021-12-310USD365
2020-06-01 to 2020-12-310USD214

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2021-01-01 to 2021-12-312,400USD365
2020-06-01 to 2020-12-311,600USD214
2020-03-30 to 2020-05-310USD63

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2021-01-01 to 2021-12-310USD365
2020-06-01 to 2020-12-3163USD214
2020-03-30 to 2020-05-310USD63

Inspect the source

Entity
MOSAIC IMMUNOENGINEERING, INC. / CIK 0000836564
Captured
2026-09-19T15:08:56.564Z
SEC response SHA-256
20b7dbddee8b1aee5cb56cb4cf5c3c14c36ef1fafb538ec0211cfb2585ddf3fd

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000836564.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))